Sarep­ta's Ex­ondys 51 is not cost-ef­fec­tive, nor par­tic­u­lar­ly ben­e­fi­cial for DMD pa­tients — ICER

Par­ents with chil­dren suf­fer­ing from Duchenne mus­cu­lar dy­s­tro­phy (DMD) — a rare, pro­gres­sive mus­cle wast­ing dis­ease that dis­pro­por­tion­ate­ly af­fects young boys — cheered in 2016 when Sarep­ta Ther­a­peu­tics’ Ex­ondys 51 (eteplirsen) was con­tro­ver­sial­ly ap­proved by the FDA, un­der pres­sure from pa­tient ad­vo­cates and de­spite stiff op­po­si­tion from with­in and out­side the agency. Crit­ics lam­bast­ed the agency’s de­ci­sion, cit­ing in­suf­fi­cient da­ta — and now, an in­creas­ing­ly in­flu­en­tial ICER has con­curred: The un­der­ly­ing ev­i­dence sup­port­ing the drug is sparse, and giv­en its cur­rent pric­ing, it is cer­tain­ly not cost-ef­fec­tive.

There are rough­ly 6,000 young boys suf­fer­ing from DMD — caused by the ab­sence of dy­s­trophin, a pro­tein that helps keep mus­cle cells in­tact — in the Unit­ed States. Symp­toms tend to kick in and pro­gres­sive­ly wors­en be­tween the ages of 3 to 5, lead­ing the pa­tient to be typ­i­cal­ly wheel­chair-bound by their ear­ly teens. Even­tu­al­ly, pa­tients suc­cumb to the dis­ease by their 30s. Cor­ti­cos­teroids, which work by di­min­ish­ing in­flam­ma­tion and lim­it­ing the im­mune sys­tem’s ac­tiv­i­ty, are com­mon­ly used to treat DMD.

The gener­ic steroid pred­nisone is al­so fre­quent­ly used to treat DMD. In 2017, the cor­ti­cos­teroid de­flaza­cort, brand­ed Em­flaza, was al­so sanc­tioned FDA ap­proval, with an eye-pop­ping $89,000-per-pa­tient an­nu­al price tag by Marathon Phar­ma­ceu­ti­cals. Marathon did not in­vent the drug, and pre­vi­ous­ly US pa­tients had been able to im­port it for as lit­tle as $1,000. Un­der fire for its pric­ing, Marathon agreed to be ac­quired by PTC Ther­a­peu­tics $PTCT, which pledged to re­duce the price.

ICER eval­u­at­ed the ef­fi­ca­cy, safe­ty and cost-ef­fec­tive­ness of four treat­ments, in its draft re­port on Wednes­day. It looked at the steroids de­flaza­cort and pred­nisone — as well as the ex­on-skip­ping drugs: the ap­proved eteplirsen and the ex­per­i­men­tal golodirsen (both come from Sarep­ta $SRPT, and each treat­ment is de­signed to treat a dif­fer­ent sub­set of DMD pa­tients).

Over­all, the ev­i­dence sup­port­ing each of the four treat­ments is lack­ing, and their im­pact on pa­tients un­clear, ICER found.

De­spite ev­i­dence that cor­ti­cos­teroid treat­ment ben­e­fits all DMD pa­tients, the “op­ti­mal dos­ing…and du­ra­tion of ther­a­py re­main un­clear. Rel­a­tive­ly small clin­i­cal tri­als have pro­vid­ed on­ly short-term ef­fi­ca­cy da­ta, even though long-term use…is the norm,” ICER re­view­ers said. “Al­though ob­ser­va­tion­al stud­ies have pro­vid­ed longer-term da­ta, un­cer­tain­ty about the nat­ur­al his­to­ry of the dis­ease, lack of con­sis­tent dos­ing and out­come mea­sures, and a pauci­ty of com­par­i­son da­ta be­tween cor­ti­cos­teroids leave a sub­stan­tial gap in un­der­stand­ing the ef­fi­ca­cy and ad­verse ef­fects of long term steroid ther­a­py, par­tic­u­lar­ly with re­spect to dif­fer­ences be­tween de­flaza­cort and pred­nisone.”

Ob­ser­va­tion­al — but in­con­sis­tent — da­ta sug­gests there may be some greater ben­e­fit on mo­tor func­tion with de­flaza­cort, and the mag­ni­tude of the ben­e­fits may be small, re­view­ers said, adding that de­flaza­cort has not been shown to im­prove pul­monary func­tion out­comes com­pared with pred­nisone. Giv­en the side-ef­fects of cor­ti­cos­teroids, de­flaza­cort has been in the spot­light for its po­ten­tial of small­er ad­verse-events: Un­de­sired weight gain ap­pears to be greater with pred­nisone than de­flaza­cort, while cataract for­ma­tion and re­duc­tion in growth ap­pear to be greater with de­flaza­cort, the non-prof­it found.

For ex­on-skip­ping ther­a­pies — which are de­signed to work by skip­ping the delet­ed ex­on, al­low­ing the re­main­der to join and form a com­plete gene to boost dy­s­trophin pro­duc­tion — da­ta are “lim­it­ed to sur­ro­gate out­comes from very small tri­als, and the thresh­old for dy­s­trophin ex­pres­sion suf­fi­cient for mean­ing­ful clin­i­cal im­prove­ment has yet to be de­fined,” re­view­ers said, not­ing that over­all, eteplirsen and golodirsen treat­ment re­sults “in very small in­creas­es in dy­s­trophin.”

Ex­treme­ly lim­it­ed ran­dom­ized da­ta for eteplirsen did not show im­prove­ments in the six-minute walk test, ver­sus place­bo — al­though no func­tion­al out­come re­sults have been re­port­ed for golodirsen. The safe­ty pro­file of eteplirsen ap­pears to be be­nign, and no safe­ty da­ta are yet avail­able golodirsen, they added.

ICER con­duct­ed its cost-ef­fec­tive­ness analy­sis us­ing qual­i­ty-ad­just­ed-life-years (QALYs), a mea­sure of the state of health of a per­son or group in which the ben­e­fits — in terms of length of life — are ad­just­ed to re­flect the qual­i­ty of life.

DMD drug dos­ing is weight-based, and ICER used to cal­cu­late cost-ef­fec­tive­ness us­ing an­nu­al cost es­ti­mates for a 40 kg pa­tient.

Source: ICER

Click on the im­age to see the full-sized ver­sion

Based on the avail­able ev­i­dence, when com­pared to pred­nisone, de­flaza­cort is pro­ject­ed to have very high costs rel­a­tive to its ben­e­fits, ICER said.

The ICER re­port does not ac­cu­rate­ly rep­re­sent Em­flaza’s re­al val­ue, a PTC spokesper­son told End­points News in an emailed state­ment. “ICER’s re­liance on the QALY stan­dard is not par­tic­u­lar­ly use­ful for eval­u­at­ing the ac­tu­al needs of in­di­vid­ual pa­tients with rare dis­or­ders and the im­pact Em­flaza has on the lives of pa­tients and fam­i­lies…”.

In ad­di­tion, “(P)reser­va­tion of am­bu­la­tion and up­per ex­trem­i­ty func­tion were not re­flect­ed in the cost analy­sis giv­en the da­ta demon­strat­ed that pa­tients tak­ing de­flaza­cort were able to have near­ly an ad­di­tion­al 3 years of am­bu­la­tion over pa­tients tak­ing pred­nisone,” the spokesper­son added.

For eteplirsen, at its cur­rent price, no plau­si­ble treat­ment ef­fects were found to make this treat­ment reach cost-ef­fec­tive­ness thresh­olds be­low the $150,000 bench­mark, per QALY gained. Sim­i­lar re­sults are ex­pect­ed of golodirsen if it is priced sim­i­lar to eteplirsen, ICER con­clud­ed.

Sarep­ta, un­sur­pris­ing­ly, was not hap­py with ICER’s find­ings. In a state­ment, the com­pa­ny called the in­sti­tute’s ap­proach “fa­tal­ly flawed” as it re­lates to rare and ge­net­ic dis­ease and ill-equipped to “ac­com­mo­date the FDA ac­cel­er­at­ed ap­proval process”.

“If the goal is to sup­port a cost ef­fec­tive­ness ap­proach that pro­motes true in­no­va­tion while act­ing as a watch­dog for waste in the sys­tem, ICER is fail­ing,” Sarep­ta said on Thurs­day.

ICER’s DMD draft re­port is now open to pub­lic com­ment un­til June 18. Akin to NICE in the UK, ICER is an in­de­pen­dent body that an­a­lyzes the cost-ef­fec­tive­ness of drugs and oth­er med­ical ser­vices in the Unit­ed States. Un­like NICE, though, ICER is not gov­ern­ment-af­fil­i­at­ed, but its de­ter­mi­na­tions are be­com­ing in­creas­ing­ly piv­otal with re­spect to pay­ers and law­mak­ers.


Im­age: Kristof­fer Trip­plaar for Sipa USA. AP Im­ages

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly set to in­vest $2.1B in home state man­u­fac­tur­ing boost

Eli Lilly is looking to expand its footprint in its home Hoosier State by making a major investment in manufacturing.

The pharma is investing $2.1 billion in two new manufacturing sites at Indiana’s LEAP Lebanon Innovation and Research District in Boone County, northwest of Lilly’s headquarters in Indianapolis.

The two new facilities will expand Lilly’s manufacturing network for active ingredients and new therapeutic modalities, including genetic medicines, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er and CD­MOs ramp up Paxlovid man­u­fac­tur­ing with Kala­ma­zoo plant ex­pan­sion lead­ing the way

As the Covid-19 pandemic continues to evolve, pharma companies and manufacturers are exploring how to step up production on antivirals.

Pfizer is planning to expand its Kalamazoo-area facility to increase manufacturing capabilities for the oral Covid-19 antiviral Paxlovid, according to a report from Michigan-based news site MLive. The expansion of the facility, which serves as Pfizer’s largest manufacturing location, is expected to create hundreds of “high-skilled” STEM jobs, MLive reported. No details about the project’s cost and timeline have been released, but according to MLive, Pfizer will announce the details of the expansion at some point in early June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

FDA spells out the rules and re­stric­tions for states seek­ing to im­port drugs from Cana­da

The FDA is offering more of an explanation of the guardrails around its program that may soon allow states to import prescription drugs in some select circumstances from Canada, but only if such imports will result in significant cost reductions for consumers.

While the agency has yet to sign off on any of the 5 state plans in the works so far, and PhRMA’s suit to block the Trump-era rule allowing such imports is stalled, the new Q&A guidance spells out the various restrictions that states will have to abide by, potentially signaling that a state approval is coming.

Pfizer CEO Albert Bourla at the World Economic Forum (Gian Ehrenzeller/Keystone via AP Images)

All about ac­cess: Pfiz­er moves to a non-prof­it mod­el for drug sales in 45 low­er-in­come coun­tries

Leading the way to increase access to cheaper drugs worldwide, Pfizer said Wednesday it will provide all current and future patent-protected medicines and vaccines available in the US or EU on a not-for-profit basis to about 1.2 billion people in 45 lower-income countries.

Rwanda, Ghana, Malawi, Senegal and Uganda are the first five countries to sign on to this accord, which will also seek to blaze new paths for quick and efficient regulatory and procurement processes to reduce the usual delays in making new medicines and vaccines available in these countries.

US sees spike in Paxlovid us­age as Mer­ck­'s mol­nupi­ravir and As­traZeneca's Evusheld are slow­er off the shelf

New data from HHS show that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing a streak of increased usage of the pill, and signaling not only rising case numbers but more awareness of how to access it.

In comparison to this week, about 670,000 courses of the Pfizer pill have been administered across the first five months since Paxlovid has been on the US market, averaging about 33,000 courses administered per week in that time.

Almirall is tapping artificial intelligence on behalf of its sales force for insights and efficiencies. (via Shutterstock)

Almi­rall rolls out sales rep ar­ti­fi­cial in­tel­li­gence sys­tem, cut­ting pre-call prep and 'wind­shield time'

Dermatology specialty pharma Almirall is making its sales reps smarter. Not with extra training or educational courses, but instead with artificial intelligence tools.

It began a soft launch of a sales rep AI and machine learning platform it calls Polaris last August in one of its 7 US coverage regions. The platform from Aktana gathers information from across Almirall internal sources and external ones – such as claims and prescribing data – to generate insights for reps. Now, instead of spending hours prepping for a sales call, Polaris can generate details about a physician’s preferences, past behaviors and prescription habits for reps in minutes, said Almirall head of commercial operations Vincent Cerio.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Te­va, Al­ler­gan reach yet an­oth­er opi­oid set­tle­ment — ef­fec­tive­ly end­ing WV tri­al

Teva and Allergan have reached settlements with multiple states over their involvement in the opioid crisis. Their latest is worth 9 figures.

West Virginia attorney general Patrick Morrisey announced the newest settlement, worth $161.5 million, at a press conference on Wednesday. The deal would resolve claims that the companies helped fuel the state’s opioid epidemic. If it goes through, it could become the largest state-negotiated settlement in West Virginia’s history, according to Reuters.

Roche un­veils three new mon­key­pox tests as cas­es rise

Health experts maintain that the current monkeypox situation is a stark contrast to Covid. Even so, a handful of biotechs have sprung to action, including Roche, who quickly developed a set of three tests to detect the virus.

Roche and subsidiary TIB Molbiol unveiled their Lightmix Modular Virus test kits on Wednesday — three unique test kits that can help track the spread of monkeypox.

The first kit detects orthopoxviruses, including all monkeypox viruses originating from the West African and Central African forms of the virus. The second kit is a specific test that detects monkeypox viruses only, while the third simultaneously tests for both orthopoxviruses and monkeypox viruses.